Oncothyreon Inc., a clinical-stage biopharmaceutical company, focuses primarily on the development of therapeutic products for the treatment of cancer. The company’s clinical-stage product candidates include ONT-380, an orally active and selective small-molecule HER2 inhibitor, and ONT-10, a therapeutic vaccine targeting the Mucin 1 peptide antigen (MUC1). The company is developing preclinical product candidates in oncology, and potentially certain rare diseases, using its acquired protocell technology. The company also collaborates with partners to discover and develop additional product candidates. The company is developing ONT-380 for the treatment of HER2-positive metastatic breast cancer. ONT-380 is a small molecule inhibitor of HER2, also known as ErbB2, a receptor tyrosine kinase that is over-expressed in breast cancer and other cancers, such as gastric and ovarian cancer. The company has a license agreement with Array BioPharma Inc. to develop, manufacture and commercialize ONT-380. The company is conducting two Phase 1b trials of ONT-380, one in combination with Kadcyla (ado-trastuzumab emtansine or TDM-1) and another in combination with Xeloda (capecitabine) and/or Herceptin (trastuzumab). In 2014, the company announced that interim data from these Phase 1b trials indicated preliminary clinical activity and tolerability in a heavily pretreated patient population. The company is conducting a Phase 1 trial for ONT-10, a cancer vaccine directed against the MUC1. The company is also conducting a Phase 1b trial of ONT-10 in combination with the T-cell agonist antibody varlilumab in collaboration with Celldex Therapeutics, Inc. The company is developing a series of highly potent, selective, and orally active Chk1 inhibitors in collaboration with Sentinel Oncology Ltd. The company initiated collaboration with Adimab LLC for the discovery of novel antibodies against undisclosed immunotherapy targets in oncology. Strategy The company’s strategy is primarily focused on the development of therapeutic products for the treatment of cancer. Its pipeline includes the clinical-stage product candidates, ONT-380 and ONT-10, and a pre-clinical inhibitor of checkpoint kinase 1. The Key elements of the company’s strategy are to advance its clinical stage product candidates; increase its product pipeline through discovery research and preclinical development; acquire or in-license attractive product candidates and technologies; and support its internal activities with strategic collaborations and out-licensing. Patents and Proprietary Information As of December 31, 2014, the company owned approximately 15 U.S. patents and patent applications, as well as the corresponding foreign patents and patent applications and held exclusive or partially exclusive licenses to 21 U.S. patents and patent applications, as well as the corresponding foreign patents and patent applications. Research and Development During the year ended December 31, 2014, the company expended approximately $41.9 million on research and development activities. History Oncothyreon Inc. was founded in 1985. The company was incorporated in 1985 in Canada under the name Biomira Inc. in 2005.
oncothyreon inc (ONTY:NASDAQ GS)
2601 Fourth Avenue
Seattle, WA 98121
|No competitor information is available for ONTY.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact ONCOTHYREON INC, please visit www.oncothyreon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.